Phase 3 Clinical Trials With Primary Completion Dates in August 2016

This is a list of Phase 3 trials with primary completion dates in August 2016 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ATRS Antares Pharma, Inc. 2016-08-01 Phase 3 NCT02504541 Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism (STEADY)
CTIC CTI BioPharma Corp. 2016-08-01 Phase 3 NCT02055781 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
CVM Cel-Sci Corporation 2016-08-01 Phase 3 NCT01265849 Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity
INNL Innocoll Holdings 2016-08-01 Phase 3 NCT02427802 Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers
ITCI Intra-Cellular Therapies Inc. 2016-08-01 Phase 3 NCT02469155 A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment
MNK Mallinckrodt plc 2016-08-01 Phase 3 NCT01520545 Safety Study of 3 mg/mL Baclofen Injection (Intrathecal) Using A Programmable Pump
TARO Taro Pharmaceutical Industries Ltd. 2016-08-01 Phase 3 NCT02618759 Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis
TBPH Theravance Biopharma, Inc. 2016-08-01 Phase 3 NCT02512510 Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
TBPH Theravance Biopharma, Inc. 2016-08-01 Phase 3 NCT02459080 Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)